HUTCHMED (NASDAQ:HCM) has announced that its New Drug Application (NDA) for tazemetostat, intended for adult patients with relapsed or refractory follicular lymphoma, has been accepted for review by the China National Medical Products Administration (NMPA).

The NDA has also been granted Priority Review status.

The NDA submission is bolstered by a Phase II bridging study conducted in China, alongside clinical trials performed by Epizyme outside the country.

Intrestingly, tazemetostat is already approved in the U.S. and Japan for similar indications.

The drug is a first-in-class methyltransferase inhibitor of EZH2, developed by Epizyme.